DDO-2093

Cat. No.: HY-132233: FAQs
Data Sheet Handling Instructions Technical Support

DDO-2093 is a potent MLL1-WDR5 protein-protein interaction inhibitor (IC₅₀=8.6 nM; K_d=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (DDO-2093 dihydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

DDO-2093 Chemical Structure

CAS No. : 2250024-74-7

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of DDO-2093:

DDO-2093 dihydrochloride Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Histone Methyltransferase Isoform Specific Products:

View All Isoforms

EZH1 EZH2 DOT1L SMYD2 SMYD3 SUV39H2/KMT1B EHMT2/G9a/KMT1C EHMT1/GLP/KMT1D SETDB1/KMT2G SETD2/KMT3A NSD2/MMSET/WHSC1 SETD7/KMT7 SETD8/KMT5A PRMT1 PRMT3 PRMT4 PRMT5 PRMT6 PRMT7 PRMT8

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
HUVEC	IC₅₀	> 100 μM Compound: 24; DDO-2093	Cytotoxicity against HUVEC assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against HUVEC assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 34225179]
MOLM-13	GI₅₀	9.9 μM Compound: DDO-2093	Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay	[PMID: 34283608]
MOLM-13	IC₅₀	9.9 μM Compound: 24; DDO-2093	Antiproliferative activity against human MOLM-13 cells harboring MLL-AF9 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Antiproliferative activity against human MOLM-13 cells harboring MLL-AF9 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 34225179]
MV4-11	GI₅₀	8 μM Compound: DDO-2093	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell proliferation measured after 5 days by ATPlite assay	[PMID: 34283608]
MV4-11	IC₅₀	8 μM Compound: 24; DDO-2093	Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as reduction in cell viability measured after 72 hrs by CCK8 assay	[PMID: 34225179]
MV4-11	IC₅₀	8000 nM Compound: DDO-2093	Anti-proliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as inhibition of cell viability treated for 72 hrs by CCK-8 assay Anti-proliferative activity against human MV4-11 cells harboring MLL-AF4 fusion protein assessed as inhibition of cell viability treated for 72 hrs by CCK-8 assay	[PMID: 35436124]

In Vitro

DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9 and Meis1)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MV4-11 cells
Concentration:	1, 2.5, 5, and 10 μM
Incubation Time:	7 days
Result:	Dose-dependently reduced the mono-, di-, and trimethylation of H3K4.

In Vivo

DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nude mice (MV4-11 human leukemia cancer xenografts)^[1]
Dosage:	20 mg/kg, 40 mg/kg and 80 mg/kg
Administration:	Intraperitoneal injection; every other day for 21 days
Result:	Had the tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.

Molecular Weight

614.11

Formula

C₂₉H₃₇ClFN₉O₃

CAS No.

2250024-74-7

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CN(C2=CC=C(N3CCN(C)CC3)C(NC(C4=CC(N)=C(F)C(C)=C4Cl)=O)=C2)N=N1)NCCCN5CCOCC5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Chen W, et al. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity [published online ahead of print, 2021 Jun 28]. Eur J Med Chem. 2021;223:113677. [Content Brief]

DDO-2093 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DDO-20932250024-74-7DDO2093DDO 2093Histone MethyltransferaseMLL1WDR5antitumorcatalyticcomplexMV4-11leukemiacancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *